Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Correlation between serum adenosine deaminase activity and efficacy of anti-programmed cell death-1 antibody.

Saiki M, Yoshizawa T, Dotsu Y, Ariyasu R, Koyama J, Sonoda T, Uchibori K, Nishikawa S, Kitazono S, Yanagitani N, Horiike A, Nishio M.

Lung Cancer. 2019 Jul;133:4-9. doi: 10.1016/j.lungcan.2019.04.022. Epub 2019 Apr 27.

PMID:
31200826
2.

Lung Adenocarcinoma with Lynch Syndrome and the Response to Nivolumab.

Kawashima Y, Nishikawa S, Ninomiya H, Yoshida R, Takano N, Oguri T, Kitazono S, Yanagitani N, Horiike A, Ohyanagi F, Ishikawa Y, Nishio M.

Intern Med. 2019;58(10):1479-1484. doi: 10.2169/internalmedicine.1673-18. Epub 2019 May 15.

3.

Improvement in the survival of patients with stage IV non-small-cell lung cancer: Experience in a single institutional 1995-2017.

Takano N, Ariyasu R, Koyama J, Sonoda T, Saiki M, Kawashima Y, Oguri T, Hisakane K, Uchibori K, Nishikawa S, Kitazono S, Yanagitani N, Ohyanagi F, Horiike A, Gemma A, Nishio M.

Lung Cancer. 2019 May;131:69-77. doi: 10.1016/j.lungcan.2019.03.008. Epub 2019 Mar 21.

PMID:
31027701
4.

Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA.

Otsubo K, Sakai K, Takeshita M, Harada D, Azuma K, Ota K, Akamatsu H, Goto K, Horiike A, Kurata T, Nakagaki N, Nosaki K, Iwama E, Nakanishi Y, Nishio K, Okamoto I.

Oncologist. 2019 Apr 25. pii: theoncologist.2019-0101. doi: 10.1634/theoncologist.2019-0101. [Epub ahead of print]

PMID:
31023862
5.

Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status.

Fukuda K, Takeuchi S, Arai S, Katayama R, Nanjo S, Tanimoto A, Nishiyama A, Nakagawa T, Taniguchi H, Suzuki T, Yamada T, Nishihara H, Ninomiya H, Ishikawa Y, Baba S, Takeuchi K, Horiike A, Yanagitani N, Nishio M, Yano S.

Cancer Res. 2019 Apr 1;79(7):1658-1670. doi: 10.1158/0008-5472.CAN-18-2052. Epub 2019 Feb 8.

PMID:
30737231
6.

Phase 1 Study of Cabozantinib in Japanese Patients With Expansion Cohorts in Non-Small-Cell Lung Cancer.

Nokihara H, Nishio M, Yamamoto N, Fujiwara Y, Horinouchi H, Kanda S, Horiike A, Ohyanagi F, Yanagitani N, Nguyen L, Yaron Y, Borgman A, Tamura T.

Clin Lung Cancer. 2019 May;20(3):e317-e328. doi: 10.1016/j.cllc.2018.12.018. Epub 2018 Dec 31.

7.

First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors.

Shimomura A, Yamamoto N, Kondo S, Fujiwara Y, Suzuki S, Yanagitani N, Horiike A, Kitazono S, Ohyanagi F, Doi T, Kuboki Y, Kawazoe A, Shitara K, Ohno I, Banerji U, Sundar R, Ohkubo S, Calleja EM, Nishio M.

Mol Cancer Ther. 2019 Mar;18(3):531-540. doi: 10.1158/1535-7163.MCT-18-0831. Epub 2019 Jan 24.

PMID:
30679388
8.

Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance.

Okada K, Araki M, Sakashita T, Ma B, Kanada R, Yanagitani N, Horiike A, Koike S, Oh-Hara T, Watanabe K, Tamai K, Maemondo M, Nishio M, Ishikawa T, Okuno Y, Fujita N, Katayama R.

EBioMedicine. 2019 Mar;41:105-119. doi: 10.1016/j.ebiom.2019.01.019. Epub 2019 Jan 17.

9.

Exploration of germline variants responsible for adverse events of crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer by target-gene panel sequencing.

Mizugaki H, Hamada A, Shibata T, Hosoda F, Nakamura H, Okuma Y, Shukuya T, Umemura S, Horiike A, Fukui T, Kogure Y, Daga H, Urata Y, Yamada K, Saeki S, Fujisaka Y, Nakamura Y, Sato M, Yoshida T, Hotta T, Oizumi S, Fujiwara Y, Ohe Y, Fujiwara Y.

Lung Cancer. 2019 Feb;128:20-25. doi: 10.1016/j.lungcan.2018.12.002. Epub 2018 Dec 4.

PMID:
30642448
10.

Phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advanced non-small cell lung cancer.

Kawano Y, Sasaki T, Yamaguchi H, Hirano K, Horiike A, Satouchi M, Hosokawa S, Morinaga R, Komiya K, Inoue K, Fujita Y, Toyozawa R, Kimura T, Takahashi K, Nishikawa K, Kishimoto J, Nakanishi Y, Okamoto I.

Lung Cancer. 2018 Nov;125:136-141. doi: 10.1016/j.lungcan.2018.09.014. Epub 2018 Sep 18.

PMID:
30429011
11.

EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer.

Sonoda T, Nishikawa S, Sakakibara R, Saiki M, Ariyasu R, Koyama J, Kitazono S, Yanagitani N, Horiike A, Ohyanagi F, Ninomiya H, Ishikawa Y, Nishio M.

Respir Med Case Rep. 2018 Mar 16;24:19-21. doi: 10.1016/j.rmcr.2018.03.009. eCollection 2018.

12.

Characterization of Computed Tomography Imaging of Rearranged During Transfection-rearranged Lung Cancer.

Saiki M, Kitazono S, Yoshizawa T, Dotsu Y, Ariyasu R, Koyama J, Sonoda T, Uchibori K, Nishikawa S, Yanagitani N, Horiike A, Ohyanagi F, Oikado K, Ninomiya H, Takeuchi K, Ishikawa Y, Nishio M.

Clin Lung Cancer. 2018 Sep;19(5):435-440.e1. doi: 10.1016/j.cllc.2018.04.006. Epub 2018 May 10.

PMID:
29885946
13.

Atezolizumab in Japanese Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis of the Phase 3 OAK Study.

Hida T, Kaji R, Satouchi M, Ikeda N, Horiike A, Nokihara H, Seto T, Kawakami T, Nakagawa S, Kubo T.

Clin Lung Cancer. 2018 Jul;19(4):e405-e415. doi: 10.1016/j.cllc.2018.01.004. Epub 2018 Feb 1.

14.

Phase 1 study of ombrabulin in combination with docetaxel and cisplatin in Japanese patients with advanced solid tumors.

Nishio M, Satouchi M, Horiike A, Horio Y, Sunaga Y, Ecstein-Fraisse E, Hida T.

Jpn J Clin Oncol. 2018 Apr 1;48(4):322-328. doi: 10.1093/jjco/hyy026.

PMID:
29514256
15.

High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer.

Ariyasu R, Nishikawa S, Uchibori K, Oh-Hara T, Yoshizawa T, Dotsu Y, Koyama J, Saiki M, Sonoda T, Kitazono S, Yanagitani N, Horiike A, Inase N, Kasahara K, Nishio M, Katayama R.

Lung Cancer. 2018 Mar;117:1-6. doi: 10.1016/j.lungcan.2017.12.018. Epub 2018 Jan 4.

PMID:
29496249
16.

Dramatic response to alectinib in inflammatory myofibroblastic tumor with anaplastic lymphoma kinase fusion gene.

Saiki M, Ohyanagi F, Ariyasu R, Koyama J, Sonoda T, Nishikawa S, Kitazono S, Yanagitani N, Horiike A, Ninomiya H, Ishikawa Y, Nishio M.

Jpn J Clin Oncol. 2017 Dec 1;47(12):1189-1192. doi: 10.1093/jjco/hyx133.

PMID:
28977547
17.

Adrenal Insufficiency Related to Anti-Programmed Death-1 Therapy.

Ariyasu R, Horiike A, Yoshizawa T, Dotsu Y, Koyama J, Saiki M, Sonoda T, Nishikawa S, Kitazono S, Yanagitani N, Nishio M.

Anticancer Res. 2017 Aug;37(8):4229-4232.

PMID:
28739711
18.

Efficacy of bevacizumab and erlotinib combination for leptomeningeal carcinomatosis after failure of erlotinib.

Ariyasu R, Horiike A, Koyama J, Saiki M, Sonoda T, Kawashima Y, Takano N, Oguri T, Nishikawa S, Kitazono S, Yanagitani N, Ohyanagi F, Nishio M.

Anticancer Drugs. 2017 Jun;28(5):565-567. doi: 10.1097/CAD.0000000000000489.

PMID:
28225456
19.

EBUS-TBNA as a Promising Method for the Evaluation of Tumor PD-L1 Expression in Lung Cancer.

Sakakibara R, Inamura K, Tambo Y, Ninomiya H, Kitazono S, Yanagitani N, Horiike A, Ohyanagi F, Matsuura Y, Nakao M, Mun M, Okumura S, Inase N, Nishio M, Motoi N, Ishikawa Y.

Clin Lung Cancer. 2017 Sep;18(5):527-534.e1. doi: 10.1016/j.cllc.2016.12.002. Epub 2016 Dec 22.

PMID:
28111119
20.

A case treated with nivolumab after small cell lung cancer transformation of mutant EGFR non-small cell lung cancer.

Nishikawa S, Tambo Y, Ninomiya H, Oguri T, Kawashima Y, Takano N, Kitazono S, Ohyanagi F, Horiike A, Yanagitani N, Ishikawa Y, Nishio M.

Ann Oncol. 2016 Dec;27(12):2300-2302. doi: 10.1093/annonc/mdw431. Epub 2016 Oct 19. No abstract available.

PMID:
27760736
21.

Phase Ia/Ib study of the pan-class I PI3K inhibitor pictilisib (GDC-0941) administered as a single agent in Japanese patients with solid tumors and in combination in Japanese patients with non-squamous non-small cell lung cancer.

Yamamoto N, Fujiwara Y, Tamura K, Kondo S, Iwasa S, Tanabe Y, Horiike A, Yanagitani N, Kitazono S, Inatani M, Tanaka J, Nishio M.

Invest New Drugs. 2017 Feb;35(1):37-46. doi: 10.1007/s10637-016-0382-3. Epub 2016 Aug 27.

PMID:
27565810
22.

Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer.

Horiike A, Takeuchi K, Uenami T, Kawano Y, Tanimoto A, Kaburaki K, Tambo Y, Kudo K, Yanagitani N, Ohyanagi F, Motoi N, Ishikawa Y, Horai T, Nishio M.

Lung Cancer. 2016 Mar;93:43-6. doi: 10.1016/j.lungcan.2015.12.011. Epub 2015 Dec 30.

PMID:
26898613
23.

P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.

Katayama R, Sakashita T, Yanagitani N, Ninomiya H, Horiike A, Friboulet L, Gainor JF, Motoi N, Dobashi A, Sakata S, Tambo Y, Kitazono S, Sato S, Koike S, John Iafrate A, Mino-Kenudson M, Ishikawa Y, Shaw AT, Engelman JA, Takeuchi K, Nishio M, Fujita N.

EBioMedicine. 2015 Dec 12;3:54-66. doi: 10.1016/j.ebiom.2015.12.009. eCollection 2016 Jan.

24.

Prognostic value of (18) F-fluoroazomycin arabinoside PET/CT in patients with advanced non-small-cell lung cancer.

Saga T, Inubushi M, Koizumi M, Yoshikawa K, Zhang MR, Tanimoto K, Horiike A, Yanagitani N, Ohyanagi F, Nishio M.

Cancer Sci. 2015 Nov;106(11):1554-60. doi: 10.1111/cas.12771. Epub 2015 Oct 7.

25.

Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer or Other Tumors.

Nishio M, Murakami H, Horiike A, Takahashi T, Hirai F, Suenaga N, Tajima T, Tokushige K, Ishii M, Boral A, Robson M, Seto T.

J Thorac Oncol. 2015 Jul;10(7):1058-66. doi: 10.1097/JTO.0000000000000566.

26.

Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer.

Nishio M, Horiike A, Murakami H, Yamamoto N, Kaneda H, Nakagawa K, Horinouchi H, Nagashima M, Sekiguchi M, Tamura T.

Lung Cancer. 2015 Jun;88(3):275-81. doi: 10.1016/j.lungcan.2015.03.010. Epub 2015 Mar 19.

27.

Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lung cancer.

Nishio M, Horiike A, Nokihara H, Horinouchi H, Nakamichi S, Wakui H, Ohyanagi F, Kudo K, Yanagitani N, Takahashi S, Kuboki Y, Yamamoto N, Yamada Y, Abe M, Tahata T, Tamura T.

Invest New Drugs. 2015 Jun;33(3):632-40. doi: 10.1007/s10637-015-0227-5. Epub 2015 Mar 18.

PMID:
25777467
28.

Plasma homocysteine levels and hematological toxicity in NSCLC patients after the first cycle of pemetrexed under folate supplementation.

Tanaka H, Horiike A, Sakatani T, Saito R, Yanagitani N, Kudo K, Ohyanagi F, Horai T, Nishio M.

Anticancer Drugs. 2015 Jun;26(5):573-8. doi: 10.1097/CAD.0000000000000220.

PMID:
25714250
29.

Phase II study of docetaxel-plus-bevacizumab combination therapy in patients previously treated for advanced non-squamous non-small cell lung cancer.

Ohyanagi F, Yanagitani N, Kudo K, Kawano Y, Sakatani T, Tanimoto A, Nishizawa H, Horiike A, Hagiwara S, Horai T, Nishio M.

Anticancer Res. 2014 Sep;34(9):5153-8.

PMID:
25202107
30.

A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC).

Horinouchi H, Yamamoto N, Nokihara H, Horai T, Nishio M, Ohyanagi F, Horiike A, Nakagawa K, Terashima M, Okabe T, Kaneda H, McKee MD, Carlson DM, Xiong H, Tamura T.

Cancer Chemother Pharmacol. 2014 Jul;74(1):37-43. doi: 10.1007/s00280-014-2478-9. Epub 2014 May 8.

PMID:
24807459
31.

Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.

Horiike A, Yamamoto N, Tanaka H, Yanagitani N, Kudo K, Ohyanagi F, Ono A, Naito T, Murakami H, Horai T, Nishio M.

Anticancer Res. 2014 Apr;34(4):1975-81.

PMID:
24692734
32.

A phase II study of S-1 in relapsed small cell lung cancer.

Kudo K, Ohyanagi F, Horiike A, Miyauchi E, Tahanaka H, Yanagitani N, Saito R, Kaburaki K, Sakatani T, Horai T, Nishio M.

Mol Clin Oncol. 2013 Mar;1(2):263-266. Epub 2013 Jan 14.

33.

A feasibility study of carboplatin plus irinotecan treatment for elderly patients with extensive disease small-cell lung cancer.

Misumi Y, Nishio M, Takahashi T, Ohyanagi F, Horiike A, Murakami H, Kenmotsu H, Yamamoto N, Ishii M, Shimokawa T, Hida N, Okamoto H.

Jpn J Clin Oncol. 2014 Feb;44(2):116-21. doi: 10.1093/jjco/hyt195. Epub 2013 Dec 13.

PMID:
24338555
34.

Pemetrexed and cisplatin for advanced non-squamous non-small cell lung cancer in Japanese patients: phase II study.

Kawano Y, Ohyanagi F, Yanagitani N, Kudo K, Horiike A, Tanimoto A, Nishizawa H, Ichikawa A, Sakatani T, Nakatomi K, Hagiwara S, Ninomiya H, Motoi N, Ishikawa Y, Horai T, Nishio M.

Anticancer Res. 2013 Aug;33(8):3327-33. Erratum in: Anticancer Res. 2013 Sep;33(9):4137.

PMID:
23898099
35.

Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer.

Nishio M, Horai T, Horiike A, Nokihara H, Yamamoto N, Takahashi T, Murakami H, Yamamoto N, Koizumi F, Nishio K, Yusa W, Koyama N, Tamura T.

Br J Cancer. 2013 Aug 6;109(3):538-44. doi: 10.1038/bjc.2013.374. Epub 2013 Jul 16.

36.

Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor.

Sakai K, Horiike A, Irwin DL, Kudo K, Fujita Y, Tanimoto A, Sakatani T, Saito R, Kaburaki K, Yanagitani N, Ohyanagi F, Nishio M, Nishio K.

Cancer Sci. 2013 Sep;104(9):1198-204. doi: 10.1111/cas.12211. Epub 2013 Jul 1.

37.

Dose-escalation study of three-dimensional conformal thoracic radiotherapy with concurrent S-1 and cisplatin for inoperable stage III non-small-cell lung cancer.

Harada H, Nishio M, Murakami H, Ohyanagi F, Kozuka T, Ishikura S, Naito T, Kaira K, Takahashi T, Horiike A, Nishimura T, Yamamoto N.

Clin Lung Cancer. 2013 Jul;14(4):440-5. doi: 10.1016/j.cllc.2013.01.003. Epub 2013 Mar 27.

PMID:
23540866
38.

Serum heparan sulfate concentration is correlated with the failure of epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with lung adenocarcinoma.

Nishio M, Yamanaka T, Matsumoto K, Kimura H, Sakai K, Sakai A, Sone T, Horiike A, Koizumi F, Kasahara K, Ohira T, Ikeda N, Saijo N, Arao T, Nishio K.

J Thorac Oncol. 2011 Nov;6(11):1889-94. doi: 10.1097/JTO.0b013e3182286d41.

39.

Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer.

Horiike A, Kudo K, Miyauchi E, Ohyanagi F, Kasahara K, Horai T, Nishio M.

Br J Cancer. 2011 Oct 11;105(8):1131-6. doi: 10.1038/bjc.2011.375. Epub 2011 Sep 13.

40.

[A case of adenocarcinoma of the lung with a pulmonary thromboembolism which improved with gefitinib].

Yanagitani N, Horiike A, Kudo K, Ohyanagi F, Nishio M, Horai T.

Nihon Kokyuki Gakkai Zasshi. 2011 Apr;49(4):282-6. Japanese.

PMID:
21591457
41.

Clinicopathological findings of non-small-cell lung cancer with high serum progastrin-releasing peptide concentrations.

Kudo K, Ohyanagi F, Horiike A, Miyauchi E, Yanagitani N, Hoshi R, Satoh Y, Motoi N, Hamanaka W, Ishikawa Y, Mun M, Sakao Y, Okumura S, Nakagawa K, Horai T, Nishio M.

Lung Cancer. 2011 Dec;74(3):401-4. doi: 10.1016/j.lungcan.2011.03.019. Epub 2011 Apr 29.

PMID:
21529988
42.

Impact of serum hepatocyte growth factor on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung adenocarcinoma.

Kasahara K, Arao T, Sakai K, Matsumoto K, Sakai A, Kimura H, Sone T, Horiike A, Nishio M, Ohira T, Ikeda N, Yamanaka T, Saijo N, Nishio K.

Clin Cancer Res. 2010 Sep 15;16(18):4616-24. doi: 10.1158/1078-0432.CCR-10-0383. Epub 2010 Aug 2.

43.

A Phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors.

Fujisaka Y, Yamada Y, Yamamoto N, Horiike A, Tamura T.

Jpn J Clin Oncol. 2010 Aug;40(8):732-8. doi: 10.1093/jjco/hyq047. Epub 2010 Apr 29.

PMID:
20430774
44.

Phase II trial of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer.

Ohyanagi F, Yamamoto N, Horiike A, Harada H, Kozuka T, Murakami H, Gomi K, Takahashi T, Morota M, Nishimura T, Endo M, Nakamura Y, Tsuya A, Horai T, Nishio M.

Br J Cancer. 2009 Jul 21;101(2):225-31. doi: 10.1038/sj.bjc.6605152.

45.

Detection of epidermal growth factor receptor mutation in transbronchial needle aspirates of non-small cell lung cancer.

Horiike A, Kimura H, Nishio K, Ohyanagi F, Satoh Y, Okumura S, Ishikawa Y, Nakagawa K, Horai T, Nishio M.

Chest. 2007 Jun;131(6):1628-34.

PMID:
17565015
46.

Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors.

Yamamoto N, Horiike A, Fujisaka Y, Murakami H, Shimoyama T, Yamada Y, Tamura T.

Cancer Chemother Pharmacol. 2008 Mar;61(3):489-96. Epub 2007 May 5.

PMID:
17483950
47.

Phase II trial of gemcitabine and irinotecan in previously treated patients with small-cell lung cancer.

Ohyanagi F, Horiike A, Okano Y, Satoh Y, Okumura S, Ishikawa Y, Nakagawa K, Horai T, Nishio M.

Cancer Chemother Pharmacol. 2008 Mar;61(3):503-8. Epub 2007 May 5.

PMID:
17483949
48.

A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors.

Tamura T, Minami H, Yamada Y, Yamamoto N, Shimoyama T, Murakami H, Horiike A, Fujisaka Y, Shinkai T, Tahara M, Kawada K, Ebi H, Sasaki Y, Jiang H, Saijo N.

J Thorac Oncol. 2006 Nov;1(9):1002-9.

49.

Phase 1 clinical study of pegylated liposomal doxorubicin (JNS002) in Japanese patients with solid tumors.

Fujisaka Y, Horiike A, Shimizu T, Yamamoto N, Yamada Y, Tamura T.

Jpn J Clin Oncol. 2006 Dec;36(12):768-74. Epub 2006 Nov 9.

PMID:
17095524
50.

Pharmacokinetics and pharmacodynamics of weekly epoetin beta in lung cancer patients.

Fujisaka Y, Tamura T, Ohe Y, Kunitoh H, Sekine I, Yamamoto N, Nokihara H, Horiike A, Kodama T, Saijo N.

Jpn J Clin Oncol. 2006 Aug;36(8):477-82. Epub 2006 Aug 9.

PMID:
16901911

Supplemental Content

Loading ...
Support Center